RGNX
HOLD / NEUTRALMeanRevComposite
44.90
Technical
40.90
Fundamental
46.20
Rank
—
Price
9.66
Hurst
0.24
As of
Aug 31, 2026
Daily
REGENXBIO Inc.
HealthcareBiotechnologyREGENXBIO Inc. is a clinical-stage biotech firm developing treatments that use modified viruses to deliver therapeutic genes into cells affected by genetic disorders. The company's pipeline includes candidates targeting retinal diseases, muscular dystrophy, and metabolic storage disorders, all based on its proprietary viral delivery technology. REGENXBIO also licenses its platform to other pharmaceutical companies and maintains partnerships with AbbVie and Nippon Shinyaku to advance select programs internationally.
Market cap
$475.3M
P/E (trailing)
—
P/E (forward)
-2.44
PEG ratio
—
Dividend yield
0.00%
Beta
1.13
52w range
5.46 – 16.19
Return on equity
-137.63%
Profit margin
-112.58%
Revenue growth
+405.70%
Earnings growth
—
Price history
1Y: 7.20 (-43.6%) · range 5.65–15.98
Cycle position
15/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 75 · GOOD SETUP · exit proximity 0
Conviction
45/ 100 · maturity 0%
Buildup.337
EMA entry setup.4275
Fundamentals.2546
Volume profile
POC
8.06
Price vs POC
-10.7%
Overhead supply
75%
Runway
+0.4%
Value area 6.08–10.46 · 75% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -14.95% | -0.34% | mature |
| 40d | -23.74% | -0.34% | 33/40d |